Abstract
Background Coronavirus disease 2019 (COVID-19) in solid organ transplant (SOT) patients is associated with more severe outcomes than non-immunosuppressed hosts. However, exactly which risk factors cause Long COVID in acute COVID cases remains unknown. More importantly, the impact of Long COVID on patient survival remains understudied, especially when examined alongside the effect of SOT.
Methods All patients have been identified with acute COVID in the National COVID Collaborative Cohort registry from July 1, 2020, to June 30, 2022. We compared patient demographics in Long COVID vs. those without Long COVID based on descriptive statistics. Multivariable logistics regressions were used to determine the factors related to the likelihood of developing Long COVID from a case of acute COVID. Multi-variables Cox regression was used to determine the time-to-event outcome of patient survival with Long COVID.
Results This study reviewed data from a cohort of 6,416,500 acute COVID patients. Of that group, 31,744 (0.5%) patients developed Long COVID from ICD diagnosis. The mean (q1, q3) age was 39 (22, 57) years old, and 55% of patients were female. From this cohort, a total of 31,744 (1%) developed Long COVID and 43,565 (1%) had SOT, with a total of 698 SOT patients identified with Long COVID. Mean age of those with Long COVID was 52 (39, 64) years old and 64% of patients were female. Most of the SOT patients were kidney transplant recipients. From the Cox regression analysis of patient survival, there were many significant factors related to patient survival (death), with elderly SOT patients having a much higher hazard ratio of 27.8 (26.3, 29.4).
Conclusion This study has identified the important risk factors that are more likely to cause Long COVID in an acute COVID cohort. We investigated hazard ratios of patient survival based on multivariable Cox models, which found that Long COVID had a more direct impact on survival in elderly patients and those with SOT.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Clinical Protocols
NA
Funding Statement
NO
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective cohort study received Institutional Review Board (IRB) approval from the University of Nebraska Medical Center (0853-21-EP)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data underlying the results presented in the study are available from N3c
N3C
